 | |
| Clinical data | |
|---|---|
| Other names | 4-benzo[1,3]dioxol-5-ylbutan-2-ylhydrazine; [3-(3,4-(methylenedioxy)phenyl)-1-butyl]hydrazine; 2-piperonylisopropylhydrazine |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C11H16N2O2 |
| Molar mass | 208.261 g·mol−1 |
| 3D model (JSmol) | |
| |
Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s, but has since been discontinued alongside several old generation MAOIs in favor of the invention of RIMAs and more efficacious treatments for depression in general. [1]
See also
References
- ^ Morton I, Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 251–. ISBN 978-0-7514-0499-9.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 14 June 2023, at 15:10